Sufentanil combined with umbilical cord blood stem cells protects against myocardial infarction

doi:10.3969/j.issn.2095-4344.2016.41.013

Abstract

Abstract:

BACKGROUND: In recent years, delayed protection of drug pretreatment has become a hot spot in the field of pretreatment, and sufentanil is a non-selective opioid receptor agonist that plays a significant myocardial protective role.
OBJECTIVE: To investigate the protective effect of sufentanil combined with umbilical cord blood stem cell transplantation on injured myocardium after myocardial infarction.
METHODS: Myocardial infarction model by ligating the left anterior descending coronary artery (ischemia 30 minutes and reperfusion 180 minutes) was made in 90 healthy adult Wistar rats, and then these rat models were randomly divided into ischemia-reperfusion (IR) group, cell transplantation group, combined treatment group (n=30/group). Rats in the IR group were given intraperitoneally intravenous injection of
1 mL normal saline 5 minutes before IR; rats in the cell transplantation group were given intraperitoneally intravenous injection of 1 mL umbilical cord blood stem cell suspension 5 minutes prior to IR; and rats in the combined treatment group were given intraperitoneally intravenous injection of 10 μg/kg sufentanil 10 minutes before IR and 1 mL umbilical cord blood stem cell suspension 5 minutes prior to IR. Two weeks later, related indicators were detected.
RESULTS AND CONCLUSION: Compared with the IR group, myocardial infarct size was reduced significantly in the combined treatment group, followed by the cell transplantation group (P < 0.05). Lowest levels of serum creatine kinase, lactate dehydrogenase and troponin I were obtained in the combined treatment group followed by the cell transplantation group and IR group, while highest level of nitric oxide was observed in the combined treatment group followed by the cell transplantation group and IR group(P < 0.05). Highest expression of Caspase-3 protein was recorded in the combined treatment group, followed by the cell transplantation group and IR group (P < 0.05). Significantly increased left ventricular diastolic blood pressure and decreased left ventricular end diastolic pressure were found in the two cell transplantation groups compared with the IR group (P < 0.05). Moreover, pathological injury of the myocardial tissues was mitigated in the cell transplantation group and significantly relived in the combined treatment group compared with the IR group. In conclusion, the combined use of sufentanil and umbilical cord blood mesenchymal stem cell transplantation can reduce the degree of myocardial infarction and protect against myocardial injury.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Cord Blood Stem Cell Transplantation, Sufentanil, Myocardial Infarction, Tissue Engineering

CLC Number:

R394.2

Zhang Hong-yu. Sufentanil combined with umbilical cord blood stem cells protects against myocardial infarction[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(41): 6164-6170.

Figures/Tables 1

2.1 实验动物数量分析参加实验90只Wistar大鼠，均进入结果分析，中途无脱落。 2.2 各组心肌梗死面积比较脐血间充质干细胞组心肌梗死面积较缺血再灌注组减小，差异有显著性意义 (P < 0.05)，舒芬太尼+脐血间充质干细胞组与脐血间充质干细胞组比较心肌梗死面积明显减小，差异有显著性意义(P < 0.05)，见表1。 2.3 血清肌酸激酶、乳酸脱氢酶、心肌肌钙蛋白I、一氧化氮水平见表2。与缺血再灌注组比较，脐血间充质干细胞组血清肌酸激酶、乳酸脱氢酶及肌钙蛋白I水平明显降低，一氧化氮水平显著增加，差异有显著性意义(P < 0.05)，舒芬太尼+脐血间充质干细胞组与脐血间充质干细胞组比较，血清肌酸激酶、乳酸脱氢酶及肌钙蛋白I水平明显降低，而一氧化氮水平明显增加，差异有显著性意义(P < 0.05)。 2.4 Western blot检测Caspase-3蛋白的表达与缺血再灌注组比较，脐血间充质干细胞组Caspase-3蛋白表达明显降低，差异有显著性意义(P < 0.05)，与脐血间充质干细胞组比较，舒芬太尼+脐血间充质干细胞组Caspase-3蛋白表达明显降低，，差异有显著性意义(P < 0.05)，见图1。 2.5 血流动力学指标与缺血再灌注组比较，脐血间充质干细胞组、舒芬太尼+脐血间充质干细胞组左心室舒张压明显升高，差异有显著性意义(P < 0.05)；与缺血再灌注组比较，脐血间充质干细胞组、舒芬太尼+脐血间充质干细胞组左心室舒张末压明显降低，差异有显著性意义(P < 0.05)，见表3。 2.6 各组大鼠心肌组织病理学形态苏木精-伊红染色后病理切片可见脐血间充质干细胞组心肌细胞数量明显减少，细胞核大小不规则，细胞分界不清楚；舒芬太尼+脐血间充质干细胞组的心肌细胞数量明显多于缺血再灌注组和脐血间充质干细胞组，见图2。"

References

[1] 刘宁,王玖.急性心肌梗死患者预后影响因素分析[J].中国疗养医学,2014, 23(12):1072-1075.
[2] 黄金和.急性心肌梗死的药物治疗新进展[J].中国民族民间医药,2012,21(1):10-11.
[3] Csonka C, Kupai K, Kocsis GF, et al. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010;61(2):163-170.
[4] 荣彦生,刘义,于晗.舒芬太尼后处理对大鼠心肌缺血再灌注损伤保护作用的实验研究[J].中西医结合心血脑血管病杂志, 2011, 9(10):1228-1230.
[5] 何志裕,陆东风.人脐带血间充质干细胞移植对急性心肌梗死大鼠心功能的影响[J].血栓与止血学, 2010, 16(6): 244-249.
[6] 马会利,葛均波,钱菊英,等.骨髓干细胞移植治疗心肌梗死的临床疗效[J].心脏杂志,2008;20(5):593-595.
[7] Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12): 1210-1221.
[8] Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113(10):1287-1294.
[9] 阮光萍,姚翔,刘菊芬,等.人脐带间充质干细胞的作用：细胞移植、免疫调节及充当基因治疗靶细胞[J].中国组织工程研究,2014,18(41):6714-6718.
[10] Leor J, Guetta E, Feinberg MS, et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006;24(3):772-780.
[11] Ma N, Ladilov Y, Moebius JM, et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res. 2006;71(1): 158-169.
[12] Sadat S, Gehmert S, Song YH, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun. 2007;363(3):674-679.
[13] Siepe M, Akhyari P, Lichtenberg A, et al. Stem cells used for cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2008;34(2):242-247.
[14] Schächinger V, Aicher A, Döbert N, et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation. 2008; 118(14):1425-1432.
[15] Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg. 2007; 31(3):438-443.
[16] van den Akker F, Deddens JC, Doevendans PA, et al. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2013;1830(2):2449-2458.
[17] Henning RJ. Stem cells in cardiac repair. Future Cardiol. 2011;7(1):99-117.
[18] Chen Z, Li T, Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res. 2008;145(2):287-294.
[19] Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet. 2006;367(9509):456- 458.
[20] Kaneda K, Miyamae M, Sugioka S, et al. Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. Anesth Analg. 2008;106(1):9-16.
[21] Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56(1):127-136.
[22] Wong GT, Li R, Jiang LL, et al. Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010; 54(4):510-518.
[23] 刘鲲鹏,廖旭,薛富善,等.舒芬太尼的药理学和临床应用[J].药物临床与应用,2005,7(6):454-457.
[24] 谢丽萍,代志刚,王胜,等. 舒芬太尼预处理在大鼠肝缺血再灌注损伤中的作用及其与ｐ３８ＭＡＰＫ关系的研究[J].重庆医学,2014,43(23):3037-3039.
[25] 刘鲲鹏,孙海涛,薛富善,等.不同剂量舒芬太尼预处理对大鼠的延迟性心肌保护作用[J].中华麻醉学杂志,2009, 29(5):405-408.
[26] 李进,袁世荧,丰新民,等.舒芬太尼延迟预处理对兔心肌缺血再灌注损伤的影响[J].中麻醉学杂志,2009,29(8): 692-695．
[27] 孙海涛,薛富善,刘鲲鹏,等.COX-2和mito-KATP通道在舒芬太尼预处理对心肌缺血再灌注大鼠延迟性心肌保护中的作用[J].中华麻醉学杂志,2010,30(4):456-460.
[28] 李雅娇.人脐血间充质干细胞治疗急性心肌梗死的研究[J].中国民族民间医药,2013,22(11):106-107.
[29] 吴云,顾尔伟,方卫平,等. 舒芬太尼后处理对在体大鼠心肌缺血再灌注损伤的影响[J].安徽医科大学学报, 2011, 46(7): 652-655.
[30] 刘祥,景桂霞,白娟,等.舒芬太尼预处理对大鼠心肌缺血再灌注时PI3K/Akt的影响[J].南方医科大学学报, 2014, 34(3): 335-340.
[31] 王嘉,赵国庆,高明.舒芬太尼预处理对大鼠心肌缺血再灌注损伤的影响[J].中国实验诊断学,2012,16(7): 1162-1164.
[32] 朱健,王建刚,田首元,等.舒芬太尼后处理对大鼠心肌缺血再灌注损伤的影响及其与PI3K-Akt-eNOS的关系[J].中西医结合心脑血管病杂志,2014,12(11):1365-1367.
[33] 李军,秦建伟,梁永年,等.依达拉奉在联合瓣膜置换术中对心肌的保护作用[J].南京医科大学学报:自然科学版, 2006, 26(9): 849-851.
[34] 张启霞,秦玲.碟脉灵注射液对心肌缺血再灌注损伤大鼠心肌肌钙蛋白I、T的影响[J].中国老年学杂志,2010, 30(1):58-59.
[35] Collinson PO, Gaze DC. Biomarkers of cardiovascular damage. Med Princ Pract. 2007;16(4):247-261.
[36] 冬梅,侯春丽,常业恬,等.舒芬太尼预处理对缺血再灌注大鼠心肌梗死范围及心肌酶的影响[J].实用医学杂志, 2009, 25(15):2430-2433．
[37] 陈中青,张冬梅,贾绍斌. 舒芬太尼对大鼠心肌缺血再灌注室性心律失常的影响[J].中国心脏起搏与心电生理杂志,2009,23(3):247-249.
[38] 杨玲,梁红霞.舒芬太尼延迟性预处理对心肌缺血再灌注损伤及Caspase-3的影响[J].中华胸心血管外科杂志, 2010,26(4):269-272.
[39] Ruixing Y, Al-Ghazali R, Wenwu L, et al. Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. Scand J Clin Lab Invest. 2006;66(7):549-558.
[40] Vohra HA, Galiñanes M. Effect of the degree of ischaemic injury and reoxygenation time on the type of myocardial cell death in man: role of caspases. BMC Physiol. 2005;5:14.